Who is sponsoring NCT01593475?

NCT01593475 is sponsored by National Cancer Center, Korea.

What drugs are being tested in NCT01593475?

Interventions in NCT01593475: Induction chemotherapy followed by CCRT.

What condition does NCT01593475 study?

NCT01593475 studies Pancreatic Carcinoma Non-resectable.

Is NCT01593475 still recruiting?

NCT01593475 is currently completed. Last updated 3 January 2018.

Last reviewed 2018-01-03 · How we verify

NCT01593475

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Induction Chemotherapy With Gemcitabine and Cisplatin Followed by CCRT for Unresectable Pancreatic Carcinoma

Completed Phase 2 Last updated 3 January 2018

What this trial tests

Phase 2 trial testing Induction chemotherapy followed by CCRT in Pancreatic Carcinoma Non-resectable in 44 participants. Completed in 31 December 2016.

Timeline

5 September 2011

Primary endpoint
31 December 2016

31 December 2016

Quick facts

Lead sponsor	National Cancer Center, Korea
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	44
Start date	5 September 2011
Primary completion	31 December 2016
Estimated completion	31 December 2016
Sites	1 location across South Korea

Drugs / interventions tested

Induction chemotherapy followed by CCRT

Conditions studied

Pancreatic Carcinoma Non-resectable — all drugs for Pancreatic Carcinoma Non-resectable →

Sponsor

National Cancer Center, Korea

Who can join

18 and older, any sex, with Pancreatic Carcinoma Non-resectable. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial chose the induction chemotherapy with gemcitabine and cisplatin followed by Chemoradiotherapy (CRT) with gemcitabine to optimize the treatment for pancreas cancer patients with locally advanced disease and the purpose of this trial is to evaluate the efficacy of induction CT with gemcitabine and cisplatin followed by CRT for unresectable pancreatic carcinoma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Acquired resistance of pancreatic cancer cells to cisplatin is multifactorial with cell context-dependent involvement of resistance genes.
Mezencev R, Matyunina LV, Wagner GT, McDonald JF. · · 2016 · cited 33× · PMID 27910856 · DOI 10.1038/cgt.2016.71
Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuvant Treatment.
Yoon KA, Woo SM, Kim YH, Kong SY, et al · · 2019 · cited 18× · PMID 30970447 · DOI 10.5009/gnl18355

Verify or expand the search:

Other recruiting trials for Pancreatic Carcinoma Non-resectable

Currently open trials in the same condition.

NCT05642962 — Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) · Phase 1, PHASE2 · active not recruiting

Other National Cancer Center, Korea trials

Trials by the same sponsor.

NCT07399561 — Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy · NA · not yet recruiting
NCT07121478 — Patients With High-grade Pancreatic Neuroendocrine Tumors · Phase 2 · enrolling by invitation
NCT07171528 — Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer · Phase 2 · recruiting
NCT07125924 — Intravesical Hyaluronic Acid (HA) for Preventing Radiation Cystitis on Bladder Cancer · NA · not yet recruiting
NCT07041515 — Knowledge-enhanced Digital Intervention to Prevent Low Anterior Resection Syndrome · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01593475 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Center, Korea
Last refreshed: 3 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01593475.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing